|
Market Closed -
Toronto S.E.
03:59:50 2026-11-05 pm EST
|
5-day change | 1st Jan Change | ||
| 0.4050 CAD | 0.00% |
|
-1.22% | -10.99% |
| Oct. 14 | PharmaCorp Rx Appoints Andrew Hodson as New CFO | MT |
| Oct. 14 | PharmaCorp Rx Inc. Announces CFO Changes, Effective October 27, 2026 | CI |
Company Valuation: PharmaCorp Rx Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| Market Cap 1 | 63.34 | 75.95 | 79.78 | - | - |
| Change | - | 19.91% | 5.04% | - | - |
| Enterprise Value (EV) 1 | 63.34 | 53.55 | 86.38 | 87.23 | 84.15 |
| Change | - | -15.46% | 61.32% | 0.98% | -3.53% |
| P/E | -54x | -45.5x | 40.5x | 13.5x | - |
| PBR | - | - | - | - | - |
| PEG | - | - | -0x | 0x | - |
| Capitalization / Revenue | - | 3.64x | 1.6x | 0.83x | 0.93x |
| EV / Revenue | - | 2.56x | 1.73x | 0.91x | 0.99x |
| EV / EBITDA | - | 15.2x | 21.7x | 8.34x | 7.49x |
| EV / EBIT | - | - | 49.9x | 13.4x | 22.5x |
| EV / FCF | - | 27.9x | -77.9x | 17.1x | 11.5x |
| FCF Yield | - | 3.58% | -1.28% | 5.85% | 8.71% |
| Dividend per Share 2 | - | - | - | - | - |
| Rate of return | - | - | - | - | - |
| EPS 2 | -0.01 | -0.01 | 0.01 | 0.03 | - |
| Distribution rate | - | - | - | - | - |
| Net sales 1 | - | 20.89 | 49.96 | 95.97 | 85.37 |
| EBITDA 1 | - | 3.528 | 3.988 | 10.46 | 11.24 |
| EBIT 1 | - | - | 1.731 | 6.508 | 3.737 |
| Net income 1 | -1.013 | -1.481 | 1.5 | 6.7 | - |
| Net Debt 1 | - | -22.4 | 6.603 | 7.451 | 4.371 |
| Reference price 2 | 0.5400 | 0.4550 | 0.4050 | 0.4050 | 0.4050 |
| Nbr of stocks (in thousands) | 117,296 | 166,927 | 196,981 | - | - |
| Announcement Date | 4/22/25 | 4/29/26 | - | - | - |
1CAD in Million2CAD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 40.5x | 1.73x | 21.66x | - | 57.02M | |
| 19.6x | 0.87x | 13.04x | -.--% | 17.58B | |
| 23.06x | 0.4x | 6.15x | 1.96% | 7.07B | |
| 18.01x | 0.81x | 8.46x | 2.08% | 6.88B | |
| 21.69x | 0.82x | 14.23x | 1.15% | 6.48B | |
| 17.08x | 0.76x | 8.69x | 2.49% | 4.69B | |
| 17.07x | 1.07x | 7.54x | 2.59% | 4.85B | |
| 16.44x | 0.69x | 5.4x | 4.55% | 3.54B | |
| 14.59x | 1.24x | 7.82x | 6.02% | 3.22B | |
| 15.86x | 0.95x | 7.11x | 4.08% | 3.23B | |
| Average | 20.39x | 0.94x | 10.01x | 2.77% | 5.76B | |
| Weighted average by Cap. | 18.99x | 0.82x | 9.88x | 1.89% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- PCRX Stock
- Valuation PharmaCorp Rx Inc.
Select your edition
All financial news and data tailored to specific country editions
